ABSTRACT The idea of a fat transport system in the plasma of mammals evolved slowly over three centuries. At the turn of this century, it was discovered that plasma globulins contained lecithin and that the digestion of plasma proteins with pepsin liberated small amounts of fat and cholesterol. The high density lipoprotein (HDL) was first isolated from horse serum in 1929 and the low density lipoprotein (LDL) in 1950. It was then shown that flotation of plasma in the ultracentrifuge revealed an array of lipoproteins that included VLDL, LDL and HDL and permitted quantitation. Subsequently, it was discovered that the free fatty acids (FFA) in plasma were bound to albumin and varied with feeding and fasting. From further studies, it was concluded that lipoprotein-bound triglycerides were delivered to adipose cells for uptake after meals; during fasting, the fat cells secreted FFA, which provided fuel for many tissues. The protein components of the lipoproteins (apopeptides) were characterized in the period from 1960 to 1970 and the LDL-receptor was identified in 1974. Fat transport was then established as a receptor-mediated delivery system of lipoproteins to targeted tissues. Defects in this system due to genetically altered or absent receptors explained dyslipidemias, which promoted atherosclerosis, xanthomatosis and Alzheimer's disease.
The first inkling that a fat transport system existed in the ing, working in Germany, showed that digestion of the proteins blood of animals can be traced to Boyle in 1665. He noted of horse plasma with pepsin and HCl liberated fat (in the that after a fatty meal, the lacteals of animals appeared milky amount of 250 mg/dL) that was not extractable by ethyl ether and subsequently this emulsion entered the blood stream by from the original sample. He concluded that plasma lipids were way of the thoracic duct. In 1774, Henson showed that this bound to protein, but did not attempt to isolate an intact milky fluid contained fat, and in 1924, Gage and Fish showed lipoprotein. that blood taken from humans after a fatty meal contained tiny particles about 1 mm in diameter, which they named THE DISCOVERY OF PLASMA LIPOPROTEINS chylomicrons. This postprandial lipemia lasted for several In 1929, Michel Macheboeuf, working at the Pasteur Instihours, but was absent from fasting blood specimens. tute in Paris, reported the isolation from horse serum of a Cholesterol, a marker for all lipoproteins, was first discovstable, water-soluble lipoprotein that could be precipitated ered in bile and in gallstones by Poulletier de la Salle in 1769 from a neutral 50% saturated ammonium sulfate extract of (Dam 1958) and then rediscovered in 1815 by Chevreul, who serum by lowering the pH to 3.8. This lipoprotein contained named it ''cholesterine.'' Only later was cholesterol found in 59% protein and 41% lipid, which consisted of 18% cholesblood (Boudet 1833). In the early 19th century, biological terol and 23% phospholipid and could be redissolved in water chemists believed that the clear blood plasma from fasting to form a clear solution. Later on it was shown that this lipoanimals contained only one soluble protein, albumin, and protein was an a-globulin and had the same composition as no fat.
the a-lipoprotein that we now recognize as HDL (Table 1) . In 1886, Kauder demonstrated that when blood plasma was In 1941, Blix et al., in Upsala, observed upon electrophoretreated with 50% saturated ammonium sulfate, a new class of sis of plasma that significant amounts of lipid were associated proteins, the globulins, were precipitated, leaving the albumin with both the a-and b-globulins. In 1947, in the same Swedin solution. About the turn of the century, Haslam (1913) ish laboratory, Pederson was able to flotate a b-lipoprotein in and Chick (1914) ( Fig. 2) . Because the labeled FFA contributed õ50% of the respiratory CO 2 over 24 h, it appeared that extensive recycling families through the use of gradual changes in pH, ionic of FFA must occur. strength and ethanol concentration at low temperatures (0 to 05ЊC). As a by-product of this program, it was discovered that THE CHARACTERIZATION OF THE fractions III and IV in this orderly process contained the LIPOPROTEIN APOPEPTIDES plasma lipids. Oncley et al. (1950) isolated a b-globulin from fraction III by flotation at density 1.035 (6% NaCl) in the Attempts were then made to identify the protein compopreparative ultracentrifuge. Chemical analysis showed that this nents (apopeptides) of the major lipoproteins (Fredrickson et lipoprotein had 23% protein, 30% phospholipid, 8% free choal. 1967 ). They were delipidated with organic solvents and lesterol and 39% cholesterol esters, very close to what we now the resulting peptides fractionated and studied to determine accept as a consensus analysis for LDL (Table 1) . Fraction IV their size, shape and amino acid composition. At first, there was found to contain the high density a-lipoprotein, first isowere difficulties from the insolubility of some of the peptides lated by Macheboeuf. and the denaturation and/or proteolysis of others during isolaIn 1949, Gofman et al. from the University of California at tion. Nonetheless, by the mid-1970s, it became clear that there Berkeley proposed a new method for the quantitative measurewere four families of peptides associated with the major lipoment of serum lipoproteins using the ultracentrifuge. The low density lipoproteins were preparatively centrifuged in 1.7 mol/L NaCl (d Å 1.063). Thereafter, the high density lipoproteins were preparatively centrifuged in D 2 O containing sodium nitrate (d Å 1.21). The concentrations of lipoproteins in each set were calculated from schlieren diagrams obtained in the analytical ultracentrifuge in runs of 30-60 min. Figure 1 shows the typical patterns of VLDL, LDL and HDL from a healthy young adult. Gofman et al. (1950) were then able to associate certain lipoprotein fractions with atherosclerosis and xanthomatosis.
Another lipoprotein, Lp(a), was discovered by Käre Berg (1963) in Norway in a immunochemical study designed to detect antigenic variations in human LDL. Lp(a) is a complex particle in human plasma that is assembled from one LDL molecule that carries all the lipid and one glycoprotein [apo(a)], which has a high degree of homology to plasminogen. Lp(a) provides some risk for atherosclerosis. Table 1 presents the overall composition of these lipoproteins. There is a wide variation in their composition, ranging from 1 to 99% for protein and, reciprocally, for lipid. Figure  1 shows that all lipoproteins except free fatty acid (FFA) 2 -albumin are spheres that vary in diameter from 80 Å for HDL, to ú5000 Å for chylomicrons. FFA were discovered in plasma by Szent-Gyorgi and Tominaga in 1924 and reinvestigated by Of particular importance for lipoprotein clearance are apo B-100 and apo E. Apo B-100, with 4536 amino acids and a molecular weight of 550 kDa is the largest protein known in mammals. Apo B-48, the form of apo B present in chylomicrons, is formed in the intestine from the same gene by mRNA editing. The mRNA for apo B-100 is truncated at residue 2152 (48% of B-100) to produce a smaller apo B devoid of its binding site to the LDL receptor.
Apoprotein E has three isoforms (E-2, E-3 and E-4), two of them (E-2 and E-4) resulting from mutations that change (Table 2 ). Most lipoprotein apopeptides are synthefied the LDL receptor by affinity chromatography and detersized in the liver or the intestine, but one, apolipoprotein mined that it is a cell surface glycoprotein of 839 amino acids redundant E, is synthesized in all cells, except the gut.
that contains several domains. These include a ligand-binding domain for both B-100 and apo E, an epidermal growth factor (Fig. 3) . The receptor binds and internalizes LDL, which then latory events are mediated by a sterol regulatory element bind-
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SUPPLEMENT A precursor of HDL containing A1-, A2-and A3-apopeptides, phospholipids and free cholesterol is also synthesized in the liver and secreted into the blood. Apo A1, a co-factor for lecithin:cholesterol acyl transferase, stimulates this enzyme to transfer fatty acids from lecithin to cholesterol to form cholesterol ester, which enables HDL-3 to assume its spherical shape with a hydrophobic center and a more polar exterior. Cholesterol ester transferase protein further increases the cholesterol ester content of HDL-3 to form HDL-2 (See Fig. 1) . HDL accomplishes reverse cholesterol transport from extrahepatic tissues to the liver.
Genetic errors in the synthesis or metabolism of plasma lipoproteins or their regulatory enzymes account for the hyperand dyslipoproteinemias observed in clinical studies, which are beyond the scope of this review (Breslow 1988) . scribed by Virchow (1856) as the fundamental lesion of atherosclerosis. It is characterized by smooth muscle proliferation, accumulation of connective tissue fibers and matrix, and lipid ing protein, which monitors the free cholesterol concentration accumulation. Usually there is a fibrous cap made up of collain the cell and adjusts the expression of the cholesterol regulagen plus smooth muscle cells, and below that, a disorganized tory genes (Wang et al. 1994) . As free cholesterol levels rise, mass of lipids, cholesterol clefts, cell debris, fibrin and other the expression of LDL receptors and HMG-reductase is inhibplasma proteins. Calcification, ulceration and hemorrhage into ited and the activity of ACAT enhanced. The turnover of the plaque may occur. Thannhauser and Magendantz (1938) LDL receptors occurs partially as a result of recycling receptors were among the first to associate both atherosclerosis and xanthat have undergone endocytosis and partially by new synthethoma with high serum cholesterol levels. It is now known sis.
DISEASE STATES PROMOTED BY CHANGES
that high levels of LDL and/or b-VLDL increase the risk of atherosclerosis.
THE ROLE OF RECEPTOR MEDIATED EVENTS
On the basis of Koch's postulates, the b-lipoproteins were IN FAT TRANSPORT considered to be the agent of atherosclerosis (in a framework of agent, host and environment) by Olson (1959) and, more Knowledge of the importance of lipoprotein receptors, which feature protein-protein interactions in the clearance of recently, by Brown and Goldstein (1992) . Cholesterol per se is not the agent because LDL, which contains cholesterol, is circulating lipoproteins, has modernized views of fat transport; the pathways are shown in Figure 4 . As noted earlier, chylomipro-atherogenic whereas HDL, which also contains cholesterol, is anti-atherogenic. crons arise in the gut during fat digestion, enter the thoracic duct and then the blood stream where they are attacked by Xanthomatosis. A xanthoma is a discrete, raised yellow lesion of the skin (Addison and Gull, 1851) . Xanthomas are LPL, which reduces their triglyceride content by 75% and produces a chylomicron remnant that is taken up by B-100-E benign tumors characterized by collections of foamy histocytes. They occur in all races and both sexes in association with receptors on hepatocytes. Within the liver, the chylomicron remnant is decomposed to its amino acids and component familial or acquired disorders leading to hyperlipidemia. High plasma levels of LDL and b-VLDL produce xanthomas of diflipids. Cholesterol released from lysosomes in hepatocytes can be excreted into bile, converted into bile acids, incorporated ferent types. Alzheimer's disease. Apo E mRNA is abundant in the into VLDL for secretion into the blood via the Golgi apparatus or esterified with long-chain fatty acids and stored in the hepabrain where apo E is synthesized and secreted principally by astrocytes. Apo E-containing lipoproteins are found in the tocyte.
VLDL, the main secretory lipoprotein of the liver, contains cerebral spinal fluid and appear to play a major role in lipid transport in the central nervous system. Apo E plus a source cholesterol, phospholipid, triglyceride, newly synthesized B-100 and small amounts of E and C apopeptides. Part of the of cholesterol promotes marked neuritic extension of the dorsal root ganglion cells in culture, and apo E levels dramatically triglyceride in the VLDL is hydrolyzed by LPL to form IDL, which may be considered the VLDL remnant and which is increase after peripheral nerve injury. Apo E-4, a mutant form of apo E-3, has been implicated in then taken up by the liver. The average turnover time for chylomicron triglycerides in the blood is 7 min, whereas that the pathogenesis of Alzheimer's disease. This disorder, which features memory loss, is associated with two characteristic neufor VLDL triglycerides is about 20 min. Part of the IDL fraction is degraded by hepatic lipase to LDL, which then contains ropathologic lesions: extracellular neuritic plaques representing deposits of amyloid beta (Ab) peptide and intracellular only apo B-100. LDL is the most prominent lipoprotein in human plasma, has a turnover time of about 3 d and is cleared neurofibrillar tangles representing filaments of a microtubuleassociated protein called tau. Binding of Ab 42 to apo E-4, but principally by LDL-receptors.
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not to apo E-3, leads to plaque formation. Apo E-3 also inhibits 68: 459-475. phosphorylation of tau, which tends to prevent the formation Dam, H. (1958) Historical introduction to cholesterol. In: Chemistry, Biochemof neurofibrillar tangles, whereas apo E-4 does not affect the istry and Pathology (R. P. Cook, ed.) pp. 1-14, Academic Press, New York, NY.
phosphorylation of tau (Mahley et al. 1996) . 
